Device for simultaneous and rapid determination of the fertility hormones estradiol, progesterone, luteinizing hormone and prolactin in saliva comprising a biosensor (10) provided with four working electrodes (12, 13, 14, 15), an auxiliary electrode (11) and a reference electrode (16) and a single potentiostatic circuit (2) having a single channel, which shares the auxiliary and reference electrodes, a multiplexer (3) to multiplex the signals from the four working electrodes, a transimpedance amplifier (4), an analog-digital signal converter (5) and a controller (6).

Provided herein, in some embodiments, are methods and compositions for detecting differentially expressed genes in a sample obtained from a subject having or at risk for preeclampsia.

The present disclosure is directed toward methods for detecting brain related maladies in a subject by measuring levels of at least one of the identified biomarkers, as compared to a control. Brain related maladies include physical trauma to the brain, neurodegenerative disorders, and mental illness. The detection of the target biomarkers in ocular fluid provides a simpler and more effective sample matrix as compared to other biological matrices.

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

The disclosure provides a reversal group of biomarkers comprising a reversal pair and a reversal triplet, wherein the reversal pair and reversal triplet exhibit a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female, a reversal value for a reversal pair and a reversal triplet to determining the probability of preterm birth in the pregnant female.

The strip systems, methods, devices and associated kits disclosed herein are used to determine the presence and/or level a target analyte(s) in sample (e.g., a biological sample such as saliva or nasal swab) wherein the target analyte(s) may be a microorganism (e.g., a whole virus) or molecule (e.g., a viral antigen) associated with a healthy state, disease or injury or otherwise altered physiological condition. In certain embodiments, the systems, methods, devices and kits provide one or more improved properties relative to the lateral flow protein and other assays known in the art for the detection, including but not limited to, assay time, ease of use, risk of infection, accuracy, specificity, selectivity, limit of detection of the assay, quantitative detection and the effect of common interferents to the sensor output, cost, simplicity or a combination thereof. In certain embodiments, the systems, assays, methods and kids are multiplexed, i.e., permit detection or monitoring of more than one target analyte (e.g., two different viruses or a virus and a bacterium).

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

The present invention relates to a method for determining, predicting or estimating the biological age of a subject, or for providing a measurement for use in determining, predicting or estimating the biological age of a subject or for predicting the presence or absence of at least one disease in a subject, predicting the risk of a subject of having or developing at least one disease; and/or predicting the risk of mortality of a subject. This invention also relates to a device for determining the presence and/or amount of each biomarker in a set of biomarkers; a set of probes for determining the presence or amount of a set of biomarkers, and the use of such device and/or probes in any of the above methods. Also provided is a biomarker testing kit for use in a method as described herein and a computer-readable storage medium or a computer program comprising computer-executable instructions and associated method.

An object of the present invention is to provide a composition in which adsorption of an endocrine protein to a container is suppressed in a solution obtained by dissolving the composition in a solvent, an aqueous solution of an endocrine protein in which adsorption of an endocrine protein to a container is suppressed, an adsorption inhibitor in which adsorption of an endocrine protein to a container is suppressed, a method for suppressing adsorption, a method for measuring an amount of an endocrine protein using the composition or the aqueous solution as a standard sample, and a kit including the composition or the aqueous solution. According to the present invention, there are provided a composition containing an endocrine protein and at least two compounds selected from the group consisting of a fluorine-containing surfactant, a collagen peptide, and a milk protein; an aqueous solution containing water, an endocrine protein, and at least two compounds selected from the group consisting of the above-described surfactant, a collagen peptide, and a milk protein; an adsorption inhibitor; a method for suppressing adsorption; a method for measuring an amount of an endocrine protein; and a kit.